DK2616068T3 - Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk - Google Patents
Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk Download PDFInfo
- Publication number
- DK2616068T3 DK2616068T3 DK11760962.8T DK11760962T DK2616068T3 DK 2616068 T3 DK2616068 T3 DK 2616068T3 DK 11760962 T DK11760962 T DK 11760962T DK 2616068 T3 DK2616068 T3 DK 2616068T3
- Authority
- DK
- Denmark
- Prior art keywords
- ethyl
- imidazol
- methyl
- acid
- methylbenzyl ester
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (15)
1. Sammensætning omfattende en forbindelse med formlen I, dens individuelle enantiomerer, individuelle diastereoisomerer, hydrater, solvater, krystalformer, dens individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf til anvendelse ved sænkning af intraokulært tryk i et berørt øje hos en human patient med behov for en sådan behandling ved administration af en terapeutisk effektiv mængde af sammensætningen;
Formel I hvor R1 er H eller Ci-3-alkyl; R2 er H eller Ci-3-alkyl; R3 er H; Ci-io-alkyl; en aromatisk eller ikke-aromatisk 5- til 10-leddet monocyklisk eller bicyklisk heterocyklus, der mindst indeholder ét heteroatom, der er udvalgt fra O eller N eller S eller kombinationer deraf; eller en monocyklisk eller bicyklisk C6-io-arylgruppe; og R er en ligekædet eller forgrenet Ci-io-alkylgruppe eventuelt substitueret med aminogrupper, arylgrupper og halogenatomer, og én methylengruppe kan erstattes af carbonyl, -NH-, carboxyl, amid, -S- eller -O-; en aromatisk eller ikke-aromatisk 5- til 10-leddet monocyklisk eller bicyklisk heterocyklus, der indeholder mindst ét heteroatom, der er udvalgt fra O eller N eller S eller kombinationer deraf, hvor heterocyklussen eventuelt er substitueret med Ci-e-alkyl, amino, halogen, -O(Ci-e-alkyl), -0C(0)(Ci-e-alkyl), -C(0)0(Ci-e-alkyl), -NHC(0)(Ci-e-alkyl), -C(0)NH(Ci-e-alkyl), -S(Ci-6-alkyl) grupper; eller en monocyklisk eller bicyklisk C6-io-arylgruppe eventuelt substitueret med Ci-6-alkyl, amino, halogen, -0(Ci-6-alkyl), -0C(0)(Ci-6-alkyl), -C(0)0(Ci-e-alkyl), -NHC(0)(Ci-e-alkyl), -C(0)NH(Ci-e-alkyl) eller -S(Ci-6-alkyl) grupper.
2. Sammensætning til anvendelse ifølge krav 1, hvor forbindelsen er af formlen II, dens individuelle diastereoisomerer, hydrater, solvater, krystalformer, individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf,
Formel II hvor R1, R2, R3 og R er som defineret i krav 1
3. Sammensætning til anvendelse ifølge krav 1, hvor forbindelsen er af formlen III, dens individuelle diastereoisomerer, hydrater, solvater, krystalformer, individuelle tautomerer eller et farmaceutisk acceptabelt salt deraf,
Formel III hvor R1, R2, R3 og R er som defineret i krav 1.
4. Sammensætning til anvendelse ifølge krav 2, hvor R1 er Ci-3-alkyl, R2 er C1-3-alkyl, R3 er H og R er Ci-10-alkyl; eller hvor R1 er methyl, R2 er methyl, R3 er H og R er Ci-4-alkyl.
5. Sammensætning til anvendelse ifølge krav 2, hvor forbindelsen er udvalgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2.2- dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-amino-3-methyl-smørsyre 3-[(S)-l-(lff-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester og 2- amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eller hvor forbindelsen er udvalgt fra: iso-smørsyre 3-[(S)-l-(l-iso-butyryl-lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2.2- dimethyl-propionsyre 3-{(S)-l-[l-(2,2-dimethyl-propionyl)-lH-imidazol-4-yl]-ethyl>-2-methylbenzylester; eddikesyre 3-[(S)-l-(l-acetyl-lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; benzoesyre 3-[(S)-l-(l-benzoyl-lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3- methyl-smørsyre 2-methyl-3-{(S)-l-[l-(3-methyl-butyryl)-lH-imidazol- 4- yI]-ethyl}-benzylester; phenyl-propionsyre 2-methyl-3-{(S)-l-[l-(3-phenyl-propionyl)-lA/-imidazol-4-yl]-ethyl}-benzylester; 2-tert-butoxycarbonylamino-3-methyl-smørsyre 3-{(S)-l-[l-(2-tert-butoxy carbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2- methylbenzylester; 2-terf--butoxycarbonylamino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-{(S)-l-[l-(2-teri--butoxycarbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl>-2-methylbenzylester; 2-(2-tert-butoxycarbonylamino-3-methyI-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-tert-butoxycarbonylamino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester og 2- fe/t-butoxycarbonylamino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester.
6. Sammensætning til anvendelse ifølge krav 1, hvor det berørte øje bevarer et intraokulært tryk på mindre end det intraokulære baselinetryk i mindst otte (8) timer; eller hvor det berørte øje bevarer et intraokulært tryk på mindre end det intraokulære baselinetryk i mindst ti (10) timer, eller hvor det berørte øje bevarer et intraokulært tryk på mindre end det intraokulære baselinetryk i mindst tolv (12) timer.
7. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen omfatter 0,0005 til 5 vægt-% af en forbindelse, der er udvalgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2,2-dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3- methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester;
3-Phenyl-propionsyre 3-[(S)-l-(lAV-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester og 2- amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eller et farmaceutisk acceptabelt salt deraf; eller hvor sammensætningen omfatter 0,005 til 2 vægt-% af en forbindelse, der er udvalgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzyIester; 2.2- dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyI-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3- methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyI-benzylester; 2-amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester og 2- amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eller et farmaceutisk acceptabelt salt deraf.
8. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen omfatter 0,05 til 2 vægt-% af en forbindelse, der er udvalgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2.2- dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazoI-4-yl)-ethyl]-2-methylbenzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyI-benzylester; 3- methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazoI-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazoI-4-yl)-ethyl]-2-methylbenzylester og 2-amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eller et farmaceutisk acceptabelt salt deraf.
9. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen endvidere omfatter fra 0,001 til 1 vægt-% af et konserveringsmiddel.
10. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen endvidere omfatter fra 0,01 % til 0,5 vægt-% af et konserveringsmiddel.
11. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen endvidere omfatter fra 0,001 til 0,01 vægt-% af et konserveringsmiddel.
12. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen endvidere omfatter fra 0,01 til 1 vægt-% af et cosolvent.
13. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen endvidere omfatter fra 0,01 til 2 vægt-% af et viskositetsfremmende middel.
14. Farmaceutisk sammensætning til anvendelse ved sænkning af intraokulært tryk i et berørt øje hos et individ, hvilken sammensætning omfatter en forbindelse med en struktur
Formel II hvor R1, R2, R3 og R er som defineret i krav 1.
15. Farmaceutisk sammensætning ifølge krav 14, hvor er udvalgt fra: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2,2-dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; benzoesyre 3-[(S)-l-(ltf-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester; 2-(2-amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazo-4-yI)-ethyl]-2-methylbenzylester; 2-(2-amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester og 2-amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methylbenzylester.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38337010P | 2010-09-16 | 2010-09-16 | |
PCT/US2011/051990 WO2012037490A1 (en) | 2010-09-16 | 2011-09-16 | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2616068T3 true DK2616068T3 (da) | 2016-08-29 |
Family
ID=44675870
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16161921.8T DK3078376T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
DK19194325.7T DK3636263T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK16161922.6T DK3053576T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK11760962.8T DK2616068T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK11760963.6T DK2616069T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
DK16161923T DK3050564T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK18160174.1T DK3348264T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK18157147.2T DK3338777T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
DK16161920.0T DK3050563T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16161921.8T DK3078376T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
DK19194325.7T DK3636263T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK16161922.6T DK3053576T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11760963.6T DK2616069T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
DK16161923T DK3050564T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol |
DK18160174.1T DK3348264T3 (da) | 2010-09-16 | 2011-09-16 | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk |
DK18157147.2T DK3338777T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme |
DK16161920.0T DK3050563T3 (da) | 2010-09-16 | 2011-09-16 | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande |
Country Status (29)
Country | Link |
---|---|
US (9) | US8492422B2 (da) |
EP (13) | EP3050564B1 (da) |
JP (4) | JP2013541527A (da) |
KR (7) | KR101952457B1 (da) |
CN (5) | CN105412092B (da) |
AR (4) | AR083019A1 (da) |
AU (4) | AU2011301856C1 (da) |
BR (4) | BR112013006320B1 (da) |
CA (8) | CA2811559A1 (da) |
CL (4) | CL2013000733A1 (da) |
CY (3) | CY1121024T1 (da) |
DK (9) | DK3078376T3 (da) |
ES (10) | ES2760920T3 (da) |
HK (5) | HK1185540A1 (da) |
HU (5) | HUE049573T2 (da) |
IL (4) | IL225280A0 (da) |
MX (4) | MX2013003002A (da) |
MY (4) | MY173846A (da) |
NZ (1) | NZ608751A (da) |
PL (7) | PL2616069T3 (da) |
PT (7) | PT3050563T (da) |
RU (4) | RU2013116403A (da) |
SG (4) | SG188571A1 (da) |
SI (5) | SI3348264T1 (da) |
TR (1) | TR201909249T4 (da) |
TW (4) | TW201240662A (da) |
UA (1) | UA112973C2 (da) |
WO (4) | WO2012037453A1 (da) |
ZA (4) | ZA201302193B (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3241553B1 (en) | 2009-02-13 | 2019-04-10 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
KR101841442B1 (ko) | 2010-01-11 | 2018-03-23 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
CA2842866A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
EP2782569A1 (en) | 2011-11-21 | 2014-10-01 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
USD794650S1 (en) | 2014-11-28 | 2017-08-15 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with a graphical user interface |
CN108310442B (zh) * | 2017-01-17 | 2021-08-27 | 台北科技大学 | 眼科用组合物 |
KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
CN112661772B (zh) * | 2018-08-24 | 2022-06-10 | 杭州阿诺生物医药科技有限公司 | 干扰素基因刺激蛋白化合物及其制备方法 |
WO2022221071A1 (en) * | 2021-04-16 | 2022-10-20 | Ads Therapeutics Llc | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs |
WO2024167962A1 (en) * | 2023-02-08 | 2024-08-15 | Whitecap Biosciences Llc | Alpha-2-adrenergic agonists for improving vision |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023010A1 (en) | 1992-05-13 | 1993-11-25 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
ATE234290T1 (de) | 1993-11-15 | 2003-03-15 | Schering Corp | Phenylalkyl-imidazole als h3-rezeptor- antagonisten |
US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
MXPA05012679A (es) * | 2003-05-27 | 2006-02-08 | Sod Conseils Rech Applic | Nuevos derivados de imidazoles, su preparacion y su uso como medicamento. |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
JP2007528020A (ja) * | 2003-07-14 | 2007-10-04 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 投影装置 |
EP2335734A3 (en) * | 2003-09-12 | 2012-01-11 | Allergan, Inc. | Treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
MXPA06013649A (es) | 2004-05-25 | 2007-07-09 | Sansrosa Pharmaceutical Dev In | Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel. |
US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
EP1797043A1 (en) | 2004-09-24 | 2007-06-20 | Allergan, Inc. | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
JP2012517433A (ja) | 2009-02-06 | 2012-08-02 | アラーガン インコーポレイテッド | アルファ2bおよび/またはアルファ2cアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物 |
EP3241553B1 (en) | 2009-02-13 | 2019-04-10 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
-
2011
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active IP Right Grant
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en active Application Filing
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/da active
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/da active
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active IP Right Grant
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/da active
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Application Filing
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en active Application Filing
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en active Application Filing
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Application Discontinuation
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active IP Right Grant
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active IP Right Grant
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko not_active Application Discontinuation
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/da active
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en active Application Filing
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
-
2013
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
- 2013-11-19 HK HK13112920.5A patent/HK1185540A1/zh unknown
- 2013-11-19 HK HK13112919.8A patent/HK1185539A1/zh unknown
- 2013-11-19 HK HK13112917.0A patent/HK1185538A1/zh unknown
- 2013-11-19 HK HK13112925.0A patent/HK1185541A1/zh unknown
-
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
-
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
-
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
- 2018-12-27 HK HK18116626.8A patent/HK1257416A1/zh unknown
-
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2616068T3 (da) | Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk | |
AU2011301856B2 (en) | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |